全文获取类型
收费全文 | 1644篇 |
免费 | 88篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 23篇 |
妇产科学 | 29篇 |
基础医学 | 251篇 |
口腔科学 | 20篇 |
临床医学 | 123篇 |
内科学 | 476篇 |
皮肤病学 | 16篇 |
神经病学 | 141篇 |
特种医学 | 23篇 |
外科学 | 255篇 |
综合类 | 14篇 |
预防医学 | 130篇 |
眼科学 | 17篇 |
药学 | 79篇 |
中国医学 | 6篇 |
肿瘤学 | 130篇 |
出版年
2024年 | 4篇 |
2023年 | 13篇 |
2022年 | 7篇 |
2021年 | 37篇 |
2020年 | 16篇 |
2019年 | 58篇 |
2018年 | 73篇 |
2017年 | 47篇 |
2016年 | 37篇 |
2015年 | 57篇 |
2014年 | 55篇 |
2013年 | 61篇 |
2012年 | 127篇 |
2011年 | 152篇 |
2010年 | 93篇 |
2009年 | 59篇 |
2008年 | 130篇 |
2007年 | 129篇 |
2006年 | 110篇 |
2005年 | 142篇 |
2004年 | 110篇 |
2003年 | 86篇 |
2002年 | 90篇 |
2001年 | 2篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 4篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有1739条查询结果,搜索用时 15 毫秒
41.
Paiva B Gutiérrez NC Rosiñol L Vídriales MB Montalbán MÁ Martínez-López J Mateos MV Cibeira MT Cordón L Oriol A Terol MJ Echeveste MA de Paz R de Arriba F Palomera L de la Rubia J Díaz-Mediavilla J Sureda A Gorosquieta A Alegre A Martin A Hernández MT Lahuerta JJ Bladé J San Miguel JF;PETHEMA/GEM 《Blood》2012,119(3):687-691
The achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; however, patients who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis. Thus, the identification of these patients is highly relevant. Here, we investigate which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n = 140) and GEM2005 < 65y (n = 101) trials. Twenty-nine (12%) of the 241 patients showed unsustained CR and a dismal outcome (median overall survival 39 months). The presence of baseline high-risk cytogenetics by FISH (hazard ratio 17.3; P = .002) and persistent minimal residual disease by multiparameter flow cytometry at day +100 after HDT/ASCT (hazard ratio 8.0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated. 相似文献
42.
Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth 总被引:1,自引:0,他引:1
Abéngozar MA de Frutos S Ferreiro S Soriano J Perez-Martinez M Olmeda D Marenchino M Cañamero M Ortega S Megias D Rodriguez A Martínez-Torrecuadrada JL 《Blood》2012,119(19):4565-4576
Membrane-anchored ephrinB2 and its receptor EphB4 are involved in the formation of blood and lymphatic vessels in normal and pathologic conditions. Eph/ephrin activation requires cell-cell interactions and leads to bidirectional signaling pathways in both ligand- and receptor-expressing cells. To investigate the functional consequences of blocking ephrinB2 activity, 2 highly specific human single-chain Fv (scFv) Ab fragments against ephrinB2 were generated and characterized. Both Ab fragments suppressed endothelial cell migration and tube formation in vitro in response to VEGF and provoked abnormal cell motility and actin cytoskeleton alterations in isolated endothelial cells. As only one of them (B11) competed for binding of ephrinB2 to EphB4, these data suggest an EphB-receptor-independent blocking mechanism. Anti-ephrinB2 therapy reduced VEGF-induced neovascularization in a mouse Matrigel plug assay. Moreover, systemic administration of ephrinB2-blocking Abs caused a drastic reduction in the number of blood and lymphatic vessels in xenografted mice and a concomitant reduction in tumor growth. Our results show for the first time that specific Ab-based ephrinB2 targeting may represent an effective therapeutic strategy to be used as an alternative or in combination with existing antiangiogenic drugs for treating patients with cancer and other angiogenesis-related diseases. 相似文献
43.
44.
Garcés-Albir M García-Botello SA Esclapez-Valero P Sanahuja-Santafé A Raga-Vázquez J Espi-Macías A Ortega-Serrano J 《International journal of colorectal disease》2012,27(8):1109-1116
Purpose
To quantify the longitudinal division of the internal anal sphincter (IAS) and external anal sphincter (EAS) after fistulotomy using three-dimensional endoanal ultrasound (3D-EAUS) and correlate the results with postoperative faecal incontinence.Methods
A prospective, consecutive study was performed from December 2008 to October 2010. All patients underwent 3D-EAUS before and 8?weeks after surgery. Thirty-six patients with simple perianal fistula were included. Patients with an intersphincteric or low transphincteric fistula (<66% sphincter involved) without risk factors for incontinence underwent fistulotomy. The outcome measures were the longitudinal extent of division of the IAS and EAS in relation to total sphincter length and continence (Jorge and Wexner scores).Results
One-year follow-up revealed a 0% recurrence rate. There was a strong correlation between preoperative 3D-EAUS measurement of fistula height with intraoperative and postoperative 3D-EAUS measurement of IAS and EAS division (p?0.001). The relationship between the level of EAS division and faecal incontinence showed a significant difference in incontinence rates between fistulotomies limited to the lower two thirds of the EAS and those above this level. Five patients (13.9%) had worse anal continence after surgery, although this was mild in all patients (<3/20 Jorge and Wexner scale). There was no significant difference in continence scores before and after surgery (p?>?0.05).Conclusions
In patients without risk factors, division of the EAS during fistulotomy limited to the lower two thirds of the EAS is associated with excellent continence and cure rates. 相似文献45.
Rosiñol L García-Sanz R Lahuerta JJ Hernández-García M Granell M de la Rubia J Oriol A Hernández-Ruiz B Rayón C Navarro I García-Ruiz JC Besalduch J Gardella S López Jiménez J Díaz-Mediavilla J Alegre A San Miguel J Bladé J;PETHEMA/Spanish Myeloma Group 《Haematologica》2012,97(4):616-621
Background
Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease.Design and Methods
In the Spanish Myeloma Group 2000 trial, 80 patients with primary refractory myeloma (49 with stable disease and 31 with progressive disease), i.e. who were refractory to initial chemotherapy, were scheduled for tandem transplants (double autologous transplant or a single autologous transplant followed by an allogeneic transplant). Patients with primary refractory disease included those who never achieved a minimal response (≥25% M-protein decrease) or better. Responses were assessed using the European Bone Marrow Transplant criteria.Results
There were no significant differences in the rates of partial response or better between patients with stable or progressive disease. However, 38% of the patients with stable disease at the time of transplantation remained in a stable condition or achieved a minimal response after transplantation versus 7% in the group with progressive disease (P=0.0017) and the rate of early progression after transplantation was significantly higher among the group with progressive disease at the time of transplantation (22% versus 2%; P=0.0043). After a median follow-up of 6.6 years, the median survival after first transplant of the whole series was 2.3 years. Progression-free and overall survival from the first transplant were shorter in patients with progressive disease (0.6 versus 2.3 years, P=0.00004 and 1.1 versus 6 years, P=0.00002, respectively).Conclusions
Our results show that patients with progressive refractory myeloma do not benefit from autologous transplantation, while patients with stable disease have an outcome comparable to those with chemosensitive disease. (ClinicalTrials.gov:) NCT00560053相似文献46.
Fuster O Barragán E Bolufer P Such E Valencia A Ibáñez M Dolz S de Juan I Jiménez A Gómez MT Buño I Martínez J Cervera J Montesinos P Moscardó F Sanz MÁ 《Annals of hematology》2012,91(1):1-7
During last years, molecular markers have been increased as prognostic factors routinely screened in acute myeloid leukemia (AML). Recently, an increasing interest has been reported in introducing to clinical practice screening for mutations in the CCAAT/enhancer-binding protein ?? (CEBPA) gene in AML, as it seems to be a good prognostic factor. However, there is no reliable established method for assessing CEBPA mutations during the diagnostic work-up of AMLs. We describe here a straightforward and reliable fragment analysis method based in PCR capillary electrophoresis (PCR-CE) for screening of CEBPA mutations; moreover, we present the results obtained in 151 intermediate-risk karyotype AML patients (aged 16?C80?years). The method gave a specificity of 100% and sensitivity of 93% with a lower detection limit of 1?C5% for CEBPA mutations. The series found 19 mutations and four polymorphisms in 12 patients, seven of whom (58%) presented two mutations. The overall frequency of CEBPA mutations in AML was 8% (n?=?12). CEBPA mutations showed no coincidence with FLT3-ITD or NPM1 mutations. CEBPA mutation predicted better disease-free survival in the group of patients without FLT3-ITD, NPM, or both genes mutated (HR 3.6, IC 95%; 1.0?C13.2, p?=?0.05) and better overall survival in patients younger than 65 of this group without molecular markers (HR 4.0, IC 95%; 1.0?C17.4, p?=?0.05). In conclusion, the fragment analysis method based in PCR-CE is a rapid, specific, and sensitive method for CEBPA mutation screening and our results confirm that CEBPA mutations can identify a subgroup of patients with favorable prognosis in AML with intermediate-risk karyotype. 相似文献
47.
Mansilla Francisco JJ Díez De los Ríos Cuenca F Cabrera Azaña S Cortés Torres J Macías López MJ González Castillo JA Ferreras Duarte JL 《CANNT journal》2012,22(1):25-29
The incidence of end stage renal disease in older persons has been increasing progressively over the last 10 years. Improved survival rates with renal replacement therapy are making this increased prevalence even more pronounced. The usual risks of morbidity and requirements for specialized care associated with older people increase dramatically when they have chronic kidney disease (CKD). It has been seen that the majority of patients in hemodialysis units are over the age of 60, and have significant co-morbidities. The relationship between older age, chronic disorders and functional dependence (FD) is well known. Accordingly, nursing care planning must be designed with this in mind. The aim of this study was to assess whether the comorbidity associated with CKD modifies FD in patients on hemodialysis. We undertook a prospective longitudinal cohort study of hemodialysis outpatients in Málaga, Spain, using the Barthel test to establish FD and the Charlson comorbidity index to quantify comorbidity. All health events were analyzed to select those study patients with incident comorbidity, understood as the appearance of a new disease that could modify the Charlson comorbidity index, and determine the change in FD. Multivariate linear regression showed that the best model for predicting functional loss was that which considered comorbidity adjusted for age, particularly when it occurred as a result of hospital admission, as it was shown to have an important predictive value for the onset of a decrease in functional dependency scores in patients with CKD. 相似文献
48.
49.
Marisa Iborra Belén Beltrán Agnes Fernández-Clotet Eva Iglesias-Flores Pablo Navarro Montserrat Rivero Ana Gutiérrez Mónica Sierra-Ausin Francisco Mesonero Rocío Ferreiro-Iglesias Joaquín Hinojosa Xavier Calvet Beatriz Sicilia Carlos González-Muñoza Beatriz Antolín María González-Vivo Ana Y. Carbajo Santiago García-López Albert Martín-Cardona Gerard Surís María Dolores Martin-Arranz Ruth de Francisco Fiorella Cañete Eugeni Domènech Pilar Nos GETECCU group 《Alimentary pharmacology & therapeutics》2020,52(6):1017-1030
50.